Asabys Partners

DeepUll is a biotechnology company dedicated to developing an innovative diagnostic system for early-stage sepsis. The company's approach focuses on rapidly identifying pathogens and delivering antibiogram results within hours. By utilizing artificial intelligence, DeepUll is able to determine the infective agent and provide insights into antimicrobial susceptibility, which helps reduce unnecessary antibiotic use. This system not only enables quick detection of pathogens and antibiotic resistance without the need for prior cultivation but also allows healthcare providers to assess a patient's immunological and functional status. Consequently, DeepUll's technology empowers doctors to predict the onset and progression of sepsis, facilitating timely clinical interventions even before symptoms manifest.

Augustine Therapeutics N.V., founded in 2019 and based in Gent, Belgium, focuses on developing innovative medicines for patients suffering from Charcot-Marie-Tooth disease and other neuromuscular disorders. The company is engaged in two drug discovery programs aimed at identifying new generations of selective HDAC6 inhibitors, which are designed to address axonopathies, including Charcot-Marie-Tooth disease. These novel compounds are intended to protect against nerve degeneration and facilitate the repair of peripheral myelin and axons. By advancing these therapeutic drugs, Augustine Therapeutics aims to enhance the quality of life for patients affected by these debilitating conditions.

Quibim, headquartered in Valencia, Spain, is a leader in whole-body medical imaging analysis, providing innovative AI-based image processing technologies. Its products, utilized by pharmaceutical companies and research teams globally, focus on extracting quantitative information from radiological images. Quibim Precision®, the company's whole-body imaging ecosystem, supports a variety of applications, from disease detection to monitoring the effectiveness of new treatments. By employing an AI-first approach, Quibim enables partners to accurately identify pathologies across different body parts and imaging modalities, ultimately enhancing the diagnosis of high-incidence illnesses and assessing treatment outcomes. This commitment to leveraging advanced imaging biomarkers contributes significantly to improving human health.

INBRAIN Neuroelectronics is a medical device company based in Barcelona, Spain, that specializes in developing graphene-based neural interfaces and intelligent neuromodulation systems aimed at treating brain disorders. Founded in 2019, the company offers the world's first brain-computer interface (BCI) therapeutics platform, which integrates precise BCI decoding with micrometric modulation to provide adaptive and personalized treatments for conditions such as Parkinson's disease, epilepsy, and stroke rehabilitation. Its technology enables continuous real-time monitoring and autonomous adjustments to therapy, enhancing therapeutic outcomes while reducing side effects. INBRAIN is also engaged in strategic collaborations, including with Merck KGaA, to expand its innovative solutions into peripheral nerve and systemic disease applications, thereby advancing the field of neurotechnology and bioelectronics.

AgomAb Therapeutics N.V., based in Gent, Belgium, specializes in the development of molecular therapies aimed at regenerating damaged tissues. The company focuses on creating agonistic monoclonal antibodies, known as agomAbs, which are designed to stimulate molecular and cellular repair mechanisms. These therapies have the potential to restore organ function in patients suffering from fibrotic, inflammatory, autoimmune, and degenerative diseases. AgomAb targets biologically validated pathways, including Transforming Growth Factor β and Hepatocyte Growth Factor, while employing specialized capabilities in organ-specific small molecules and high-affinity antibodies. The company boasts a diversified clinical pipeline addressing various fibrotic conditions and possesses comprehensive research and development expertise, alongside a strong track record in business development.

Medlumics S.L., founded in 2009 and based in Tres Cantos, Spain, specializes in designing and manufacturing catheter-based systems for the treatment of supraventricular tachycardias. The company focuses on developing integrated photonic devices that utilize optical coherence tomography technology, a light-based diagnostic method providing detailed information about tissue structures. Medlumics' radiofrequency cardiac ablation system enhances the treatment process by delivering real-time visual confirmation of catheter contact and stability during tissue ablation. This innovation aims to reduce recurrence rates and technical complexity in procedures, ultimately increasing safety for patients undergoing cardiac interventions.

Augustine Therapeutics N.V., founded in 2019 and based in Gent, Belgium, focuses on developing innovative medicines for patients suffering from Charcot-Marie-Tooth disease and other neuromuscular disorders. The company is engaged in two drug discovery programs aimed at identifying new generations of selective HDAC6 inhibitors, which are designed to address axonopathies, including Charcot-Marie-Tooth disease. These novel compounds are intended to protect against nerve degeneration and facilitate the repair of peripheral myelin and axons. By advancing these therapeutic drugs, Augustine Therapeutics aims to enhance the quality of life for patients affected by these debilitating conditions.

XRHealth Ltd. is a medical technology company based in Tel Aviv, Israel, that specializes in developing virtual reality (VR) software solutions for healthcare. Founded in 2016, the company offers an array of products designed to enhance patient care and treatment outcomes. Its offerings include VRPhysio, a platform for virtual physical therapy; VRReliever, which helps manage pain through distraction; VRCogni, aimed at improving motor function in stroke and dementia patients; and VRPsyc, which provides exposure therapy for various mental health disorders. Additionally, VRCoordi is designed to aid coordination recovery in patients with Parkinson's, brain injuries, and autism. By integrating immersive technologies with licensed clinicians and advanced data analytics, XRHealth provides comprehensive telehealth services, allowing patients to access treatment from the comfort of their own homes.

AgomAb Therapeutics N.V., based in Gent, Belgium, specializes in the development of molecular therapies aimed at regenerating damaged tissues. The company focuses on creating agonistic monoclonal antibodies, known as agomAbs, which are designed to stimulate molecular and cellular repair mechanisms. These therapies have the potential to restore organ function in patients suffering from fibrotic, inflammatory, autoimmune, and degenerative diseases. AgomAb targets biologically validated pathways, including Transforming Growth Factor β and Hepatocyte Growth Factor, while employing specialized capabilities in organ-specific small molecules and high-affinity antibodies. The company boasts a diversified clinical pipeline addressing various fibrotic conditions and possesses comprehensive research and development expertise, alongside a strong track record in business development.

Gradient Denervation Technologies is a Paris-based company founded in 2019 that focuses on the development of an endovascular catheter-based medical device designed to treat pulmonary hypertension. This innovative technology aims to reduce pulmonary vascular resistance and enhance cardiovascular hemodynamics through a minimally invasive procedure. The device is built on prior research and intellectual property developed at Stanford University and offers a novel approach to pulmonary artery denervation, addressing heart failure and associated pulmonary hypertension. By providing a reliable and effective treatment option, the company seeks to improve patient outcomes in the healthcare industry.

Orikine Bio is an innovative biotechnology company specializing in tailored cytokines for treating immune-mediated disorders. The company has developed a proprietary platform focused on cytokine-based therapies aimed at addressing autoimmune and inflammatory diseases. Orikine Bio's approach emphasizes the advancement of engineered cytokines with unique biological properties, which are designed to offer transformative treatment options. By leveraging its novel platform, Orikine Bio strives to create therapies that can significantly improve the lives of patients worldwide.

Nuage Therapeutics is a pharmaceutical company dedicated to developing selective and potent drugs that target intrinsically disordered proteins, which are often associated with challenging medical conditions. The company employs innovative approaches in chemical biology and biomolecular condensation to create selective inhibitors aimed at treating diseases such as castration-resistant prostate cancer. By focusing on these complex and often "undruggable" protein targets, Nuage Therapeutics aims to address significant unmet medical needs and improve patient outcomes through targeted therapeutic solutions.

DeepUll is a biotechnology company dedicated to developing an innovative diagnostic system for early-stage sepsis. The company's approach focuses on rapidly identifying pathogens and delivering antibiogram results within hours. By utilizing artificial intelligence, DeepUll is able to determine the infective agent and provide insights into antimicrobial susceptibility, which helps reduce unnecessary antibiotic use. This system not only enables quick detection of pathogens and antibiotic resistance without the need for prior cultivation but also allows healthcare providers to assess a patient's immunological and functional status. Consequently, DeepUll's technology empowers doctors to predict the onset and progression of sepsis, facilitating timely clinical interventions even before symptoms manifest.

AgomAb Therapeutics N.V., based in Gent, Belgium, specializes in the development of molecular therapies aimed at regenerating damaged tissues. The company focuses on creating agonistic monoclonal antibodies, known as agomAbs, which are designed to stimulate molecular and cellular repair mechanisms. These therapies have the potential to restore organ function in patients suffering from fibrotic, inflammatory, autoimmune, and degenerative diseases. AgomAb targets biologically validated pathways, including Transforming Growth Factor β and Hepatocyte Growth Factor, while employing specialized capabilities in organ-specific small molecules and high-affinity antibodies. The company boasts a diversified clinical pipeline addressing various fibrotic conditions and possesses comprehensive research and development expertise, alongside a strong track record in business development.

Amelia Virtual Care is a mental health technology company with offices in Barcelona and Mountain View, specializing in a comprehensive virtual reality platform designed for mental health treatment. This platform enables professionals to address a variety of mental health disorders, including phobias, anxiety, and depression. With a workforce of over 60 employees, Amelia has successfully delivered more than 200,000 VR therapy sessions, primarily in the United States, which serves as its main market. The company's innovative platform includes multiple features and user-friendly controls, facilitating effective therapy sessions. Recent financing and a new management team are expected to enhance Amelia's growth and strengthen its clinical evidence and commercial activities.

Cara Care is a digital health platform focused on improving gut health through an app designed for patients with chronic gastrointestinal issues. The application enables users to track their dietary habits, including custom dishes and food items from an extensive database, while also recording symptoms such as pain, bloating, and emotional states. This comprehensive approach allows individuals to identify patterns and correlations between their diet and digestive health, empowering them to take control of their well-being. With a user base exceeding 700,000 patients globally, Cara Care combines behavioral, microbial, and nutritional data to offer a holistic alternative to traditional medication for digestive disorders.

Sidekick is a patient-centric digital care platform designed to enhance the management and prevention of chronic and lifestyle-related conditions. By integrating evidence-based clinical approaches with behavioral economics and gamification, Sidekick's platform empowers patients to engage in personalized wellness activities. The platform facilitates multi-chronic condition management through gamified health engagement methods, health screening, and analytics, allowing users to connect with clinicians and gain valuable data insights. Sidekick collaborates with international pharmaceutical companies, payers, and healthcare providers to prioritize patient needs and improve the overall healthcare experience, making it more accessible and efficient.

Splice Bio is a biotechnology company based in Barcelona, Spain, focused on developing innovative gene therapies using its proprietary intein platform technology. Founded in 2012 and originally named Proteodesign, S.L., the company aims to address the needs of patients suffering from incurable genetic diseases. The intein platform, developed from research in the Muir Lab at Princeton University, seeks to overcome two significant limitations of traditional adeno-associated virus (AAV) therapies: it enhances the capacity for larger gene delivery and broadens the range of tissues that can be targeted for treatment.

INBRAIN Neuroelectronics is a medical device company based in Barcelona, Spain, that specializes in developing graphene-based neural interfaces and intelligent neuromodulation systems aimed at treating brain disorders. Founded in 2019, the company offers the world's first brain-computer interface (BCI) therapeutics platform, which integrates precise BCI decoding with micrometric modulation to provide adaptive and personalized treatments for conditions such as Parkinson's disease, epilepsy, and stroke rehabilitation. Its technology enables continuous real-time monitoring and autonomous adjustments to therapy, enhancing therapeutic outcomes while reducing side effects. INBRAIN is also engaged in strategic collaborations, including with Merck KGaA, to expand its innovative solutions into peripheral nerve and systemic disease applications, thereby advancing the field of neurotechnology and bioelectronics.

Medlumics S.L., founded in 2009 and based in Tres Cantos, Spain, specializes in designing and manufacturing catheter-based systems for the treatment of supraventricular tachycardias. The company focuses on developing integrated photonic devices that utilize optical coherence tomography technology, a light-based diagnostic method providing detailed information about tissue structures. Medlumics' radiofrequency cardiac ablation system enhances the treatment process by delivering real-time visual confirmation of catheter contact and stability during tissue ablation. This innovation aims to reduce recurrence rates and technical complexity in procedures, ultimately increasing safety for patients undergoing cardiac interventions.

Koa Health B.V., founded in 2018 and based in Amsterdam with additional offices in Barcelona, the United States, and the United Kingdom, develops digital solutions aimed at enhancing mental well-being for employees. The company provides a range of products that are informed by the latest clinical research and technology. Its offerings include the koa foundation application, which supports early symptom management and mild mental health issues, and Mindset, a chat-based platform for private mental health support. Koa Health’s solutions encompass prevention, prediction, and treatment, featuring a library of evidence-based activities designed to address various mental health challenges, such as stress management, sleep improvement, and confidence building. By delivering scalable and affordable care, Koa Health aims to make mental health support accessible and effective for individuals and organizations alike.

Sidekick is a patient-centric digital care platform designed to enhance the management and prevention of chronic and lifestyle-related conditions. By integrating evidence-based clinical approaches with behavioral economics and gamification, Sidekick's platform empowers patients to engage in personalized wellness activities. The platform facilitates multi-chronic condition management through gamified health engagement methods, health screening, and analytics, allowing users to connect with clinicians and gain valuable data insights. Sidekick collaborates with international pharmaceutical companies, payers, and healthcare providers to prioritize patient needs and improve the overall healthcare experience, making it more accessible and efficient.

Splice Bio is a biotechnology company based in Barcelona, Spain, focused on developing innovative gene therapies using its proprietary intein platform technology. Founded in 2012 and originally named Proteodesign, S.L., the company aims to address the needs of patients suffering from incurable genetic diseases. The intein platform, developed from research in the Muir Lab at Princeton University, seeks to overcome two significant limitations of traditional adeno-associated virus (AAV) therapies: it enhances the capacity for larger gene delivery and broadens the range of tissues that can be targeted for treatment.

Origo Biopharma S.L. is a biotechnology company founded in 2017 and headquartered in San Cibrao das Viñas, Spain. The company specializes in the research and development of immunotherapeutic products aimed at treating severe diseases associated with TGF-β signaling dysfunction, particularly in gastrointestinal and lung conditions. Origo Biopharma focuses on developing organ-restricted drugs to meet unmet medical needs related to cancer and fibrosis, striving to provide effective treatments for these challenging health disorders.

Ona Therapeutics, S.L. is a biotechnology company based in Barcelona, Spain, founded in 2019 by Salvador Aznar-Benitah and Valerie Vanhooren. The company focuses on the discovery and development of therapeutic biologics aimed at targeting tumor metastatic-initiating cells and lipid metabolism. Ona Therapeutics develops therapies that block fat metabolism pathways in animal models of cancer and inhibit cells responsible for metastasis. This approach holds the potential to prevent the development of malignant tumors and eliminate existing ones, allowing healthcare institutions to address various metastatic cancers, including those of the oral cavity, breast, ovary, stomach, bladder, prostate, and melanoma.

INBRAIN Neuroelectronics is a medical device company based in Barcelona, Spain, that specializes in developing graphene-based neural interfaces and intelligent neuromodulation systems aimed at treating brain disorders. Founded in 2019, the company offers the world's first brain-computer interface (BCI) therapeutics platform, which integrates precise BCI decoding with micrometric modulation to provide adaptive and personalized treatments for conditions such as Parkinson's disease, epilepsy, and stroke rehabilitation. Its technology enables continuous real-time monitoring and autonomous adjustments to therapy, enhancing therapeutic outcomes while reducing side effects. INBRAIN is also engaged in strategic collaborations, including with Merck KGaA, to expand its innovative solutions into peripheral nerve and systemic disease applications, thereby advancing the field of neurotechnology and bioelectronics.

Anaconda BioMed is a medical technology company based in Barcelona, Spain, founded in 2015 by Dr. Ofir Arad and Dr. Marc Ribó. The company specializes in developing advanced healthcare devices, particularly focused on neuro-thrombectomy systems for the treatment of acute ischemic stroke (AIS). Its flagship product, the ANCD BRAIN™, is a third-generation stented aspiration thrombectomy system that comprises a delivery catheter, a funnel-shaped aspiration catheter, and a stent retriever. This innovative system is designed to conform to the artery and effectively arrest blood flow, facilitating the full extraction of thrombus without fragmentation. Anaconda BioMed aims to provide patients with immediate treatment options for stroke, significantly reducing the risk of fatality associated with this critical medical condition.

Cara Care is a digital health platform focused on improving gut health through an app designed for patients with chronic gastrointestinal issues. The application enables users to track their dietary habits, including custom dishes and food items from an extensive database, while also recording symptoms such as pain, bloating, and emotional states. This comprehensive approach allows individuals to identify patterns and correlations between their diet and digestive health, empowering them to take control of their well-being. With a user base exceeding 700,000 patients globally, Cara Care combines behavioral, microbial, and nutritional data to offer a holistic alternative to traditional medication for digestive disorders.

Ona Therapeutics, S.L. is a biotechnology company based in Barcelona, Spain, founded in 2019 by Salvador Aznar-Benitah and Valerie Vanhooren. The company focuses on the discovery and development of therapeutic biologics aimed at targeting tumor metastatic-initiating cells and lipid metabolism. Ona Therapeutics develops therapies that block fat metabolism pathways in animal models of cancer and inhibit cells responsible for metastasis. This approach holds the potential to prevent the development of malignant tumors and eliminate existing ones, allowing healthcare institutions to address various metastatic cancers, including those of the oral cavity, breast, ovary, stomach, bladder, prostate, and melanoma.

Amelia Virtual Care is a mental health technology company with offices in Barcelona and Mountain View, specializing in a comprehensive virtual reality platform designed for mental health treatment. This platform enables professionals to address a variety of mental health disorders, including phobias, anxiety, and depression. With a workforce of over 60 employees, Amelia has successfully delivered more than 200,000 VR therapy sessions, primarily in the United States, which serves as its main market. The company's innovative platform includes multiple features and user-friendly controls, facilitating effective therapy sessions. Recent financing and a new management team are expected to enhance Amelia's growth and strengthen its clinical evidence and commercial activities.